ZEARALENONE; 17924-92-4; trans-Zearalenone; (-)-Zearalenone; Mycotoxin F2; (S)-Zearalenone; Zenone; (S)-(-)-Zearalenone; (10S)-Zearalenone; C18H22O5; (3S,11E)-14,16-dihydroxy-3-methyl-3,4,5,6,9,10-hexahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione; CHEBI:10106; Compound F-2; MFCD00133085; 6-(10-Hydroxy-6-oxo-trans-1-undecenyl)-beta-resorcylic acid lactone; MLS000097901; CHEMBL454173; 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,5,6,9,10-hexahydro-14,16-dihydroxy-3-methyl-, (3S,11E)-; DTXSID0021460; F-2 toxin; 5W827M159J; (S-(E))-3,4,5,6,9,10-Hexahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione; SMR000058177; DTXCID701460; Mycotoxin F-2; ZEA; CCRIS 623; Zearalenone 100 microg/mL in Acetonitrile; Mycotoxin F2;Toxin F2; CAS-17924-92-4; HSDB 4208; NCI-C50226; (S,E)-14,16-Dihydroxy-3-methyl-3,4,5,6,9,10-hexahydro-1H-benzo[c][1]oxacyclotetradecine-1,7(8H)-dione; 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,5,6,9,10-hexahydro-14,16-dihydroxy-3-methyl-, (S)-(-)-; EINECS 241-864-0; BRN 1350216; UNII-5W827M159J; benzoxacyclotetradecin-1,7(8H)-dione; ZEARALENONE [MI]; Opera_ID_1608; ZEARALENONE [HSDB]; COMPD F-2; Epitope ID:146094; Benzoxacyclotetradec-11-en-1-one, 14,16-dihydroxy-3-methyl-7-oxo-, trans-; Resorcylic acid, 6-(10-hydroxy-6-oxo-1-undecenyl)-, mu-lactone, trans-; SCHEMBL33754; SCHEMBL33755; BSPBio_003581; Zearalenone, fungal mycotoxin; MLS000028817; MLS000888273; MLS001174881; BIDD:ER0058; SPECTRUM1505290; Zearalenone, reference material; 6-(10-Hydroxy-6-oxo-trans-1-undecenyl)-.beta.-resorcylic acid lactone; REGID_for_CID_657988; REGID_for_CID_5281576; (2E,11S)-15,17-dihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(14),2,15,17-tetraene-7,13-dione; ALBB-030793; BCP06062; EX-A3324; ZINC3881412; Tox21_201153; Tox21_303510; BBL010576; BDBM50247676; CCG-40041; HB2517; LMPK04000016; s5676; STK033813; AKOS001577898; SDCCGMLS-0066858.P001; NCGC00038520-03; NCGC00090809-01; NCGC00090809-02; NCGC00257246-01; NCGC00258705-01; (2E,11S)-15,17-dihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(18),2,14,16-tetraene-7,13-dione; (3S,11E)-3,4,5,6,9,10-Hexahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione; (S-(Z))-3,4,5,6,9,10-Hexahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione; 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,5,6,9,10-hexahydro-14,16-dihydroxy-3-methyl-, (S-(Z))-; AC-35060; VS-02573; HY-103447; CS-0027914; Z0047; C09981; Q169326; J-011439; BRD-K42017082-001-02-6; 6-(10-HYDROXY-6-OXO-TRANS-1-UNDECENYL) BETA RESORCYCLIC ACID-MU-LACTONE; (3S,11E)-14,16-dihydroxy-3-methyl-3,4,5,6,7,8,9,10-octahydro-1H-2-benzoxacyclotetradecine-1,7-dione; (3S,11E)-3,4,5,6,9,10-Hexahydro-14, 16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin- 1,7(8H)-dione; (4S,12E)-16,18-dihydroxy-4-methyl-3-oxabicyclo[12.4.0]octadeca-1(14),12,15,17-tetraene-2,8-dione; (S,E)-14,16-Dihydroxy-3-methyl-3,4,5,6,9,10-hexahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione; 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 3,4,5,6,9,10-hexahydro-14,16-dihydroxy-3-methyl-, (3S)-; 2beta-Methyl-15,17-dihydroxy-12,13-butano-1-oxacyclotetradecane-10,15(13),16,18(12)-tetraene-6,14-dione; 3,4,5,6,9,10-Hexahydro-14,16-dihydroxy-3-methyl-1H-2- benzoxacyclotetradecin-1,7(8H)-dione